Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01025570 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
A Phase 1 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01025570 is a Phase 1 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 3 participants.
The verdict
NCT01025570, a Phase 1 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to find out the effects, good and/or bad, of the combination of two drugs, gemcitabine and bosutinib, in patients with resected pancreatic cancer and whether this combination can prevent pancreatic cancer from coming back.
Interventions
- DRUG Gemcitabine, Bosutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01025570
The ClinicalTrials.gov registry entry for NCT01025570 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine, Bosutinib is the first listed.
NCT01025570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01025570 about?
NCT01025570 is a clinical study titled "A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer". The purpose of this study is to find out the effects, good and/or bad, of the combination of two drugs, gemcitabine and bosutinib, in patients with resected pancreatic cancer and whether this combination can prevent pancreatic cancer from coming back.
What is the current status of trial NCT01025570?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2010-05. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01025570?
The interventions under investigation include: Gemcitabine, Bosutinib (DRUG).
Who is sponsoring clinical trial NCT01025570?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.